COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 8 of 864 for:    LENALIDOMIDE AND Angiogenesis

RMPT for Relapsed/Refractory Multiple Myeloma (RMPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00961467
Recruitment Status : Completed
First Posted : August 19, 2009
Last Update Posted : May 10, 2016
Information provided by (Responsible Party):
Fondazione Neoplasie Sangue Onlus

Brief Summary:
After the discovery of melphalan and prednisone (MP), many clinical trials evaluated the efficacy of combination chemotherapy, such as VMCP, VBAP, MOCCA in multiple myeloma (MM) patients, without significant clinical benefit. After 40 years, the combination of MP with thalidomide (MPT) or lenalidomide (MPR) or bortezomib (MPV) have finally and consistently shown additive or synergistic effects.In advanced MM, the combination of melphalan, prednisone and thalidomide induced 12% very good partial response (VGPR) rate, while the combination of melphalan and bortezomib showed 15% near complete remission (nCR) rate. In relapsed patients, the combination of bortezomib with MPT (VMPT) induced 43% VGPR rate. Preliminary results indicate that VMPT may induce a CR rate of around 50% in newly diagnosed patients (unpublished results).In preclinical studies thalidomide showed more anti-angiogenesis activity, while lenalidomide showed more immunomodulatory effects, thus suggesting a combined clinical approach for these two drugs. The toxicity profile of lenalidomide is completely different from that of thalidomide and no cumulative toxicities are expected, again suggesting a combination approach. This study will evaluate the safety and efficacy of combining Lenalidomide, Melphalan, Prednisone and Thalidomide (R-MPT) as salvage treatment for relapsed/refractory myeloma patients. This association might further increase the response rate achieved by the standard oral MPT or MPR regimens.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Revlimid, Melphalan, Prednisone, Thalidomide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma
Study Start Date : February 2007
Actual Primary Completion Date : March 2008
Actual Study Completion Date : April 2016

Arm Intervention/treatment
Experimental: RMPT (Arm A -thalidomide 50 mg/day) Drug: Revlimid, Melphalan, Prednisone, Thalidomide
Thalidomide was administered at 50 mg/day.

Experimental: RMPT (Arm B - thalidomide 100 mg/day) Drug: Revlimid, Melphalan, Prednisone, Thalidomide
Thalidomide was administered at 100 mg/day.

Primary Outcome Measures :
  1. Myeloma response rate in terms of partial remission (PR) and very good partial remission (VGPR) [ Time Frame: 4 years ]

Secondary Outcome Measures :
  1. progression free survival and overall survival [ Time Frame: 4 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient is of a legally consenting age as defined by local regulations.
  2. Patient is, in the investigator(s) opinion willing and able to comply with the protocol requirements.
  3. Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
  4. Female patient is either post-menopausal for 24 consecutive months or surgically sterilised or agree to continuous abstinence from heterosexual sexual contact or willing to use two acceptable method of birth control at the same time (one highly effective method and one additional effective method)(Highly Effective Methods: Intrauterine device -IUD-; Hormonal -birth control pills, injections, implants-; tubal ligation; partner's vasectomy; Additional Effective Methods: Latex condom; Diaphragm; Cervical Cap) for 4 weeks prior to beginning study drug therapy, during study drug therapy (including dose interruption) and for 4 weeks after discontinuation of Lenalidomide therapy.
  5. Male patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) during study drug therapy (including dose interruption) and for 4 weeks after discontinuation of Lenalidomide therapy.
  6. Patient was previously diagnosed with symptomatic multiple myeloma based on standard criteria (12), and has measurable disease, defined as follows:

    • Secretory myeloma: any quantifiable serum monoclonal protein value (generally, but not necessarily, greater than 1 g/dL of IgG M-Protein and greater than 0.5 g/dL of IgA M-Protein) and, where applicable, urine light-chain excretion of >200 mg/24 hours;
    • Non-secretory myeloma: > 30% plasma cells in the bone marrow and at least one plasmacytoma > 2cm as determined by clinical examination or applicable radiographs (i.e., MRI or CT scan).
  7. Patient is relapsed or refractory after one or two lines of treatment
  8. Patient has a Karnofsky performance status ≥ 60%.
  9. Patient has a life-expectancy > 3 months.
  10. Patient has the following laboratory values within 14 days before Baseline (day 1 of the Cycle 1):

    • Platelet count ³ 100 x 109/L without transfusion support within 7 days before the test
    • Absolute neutrophil count ³ 1.0 x 109/L without the use of growth factors
    • Total bilirubin £ 1.5 x the ULN
    • AST (SGOT) and ALT (SGPT) £ 2.5 x ULN
    • Corrected serum calcium < 14 mg/dl (3.5 mmol/L)
    • Calculated or measured creatinine clearance: ≥ 20 mL/minute

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  2. Pregnant or beast feeding females.
  3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  4. Use of any other concomitant standard/experimental anti-myeloma drug or therapy
  5. Prior induction therapy with R-MP or M-PT association
  6. Any of the following laboratory abnormalities:

    • Platelet count < 100 ´ 109/L.
    • Absolute neutrophil count <1.0 ´ 109/L.
    • Aspartate transaminase (AST): >2.5 x the upper limit of normal (ULN).
    • Alanine transaminase (AST): > 2.5 x the ULN.
    • Total bilirubin: > 1.5 x the ULN.
    • Corrected serum calcium >14 mg/dL (3.5 mmol/L).
    • Calculated or measured creatinine clearance <20 mL/minute
  7. Known positive for HIV or active infectious hepatitis, type B or C.
  8. Patient has ³Grade 2 peripheral neuropathy within 14 days before enrollment.
  9. Known hypersensitivity to thalidomide.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00961467

Layout table for location information
Azienda Ospedaliera S Giovanni Battista
Torino, Italy/Torino, Italy, 10126
Sponsors and Collaborators
Fondazione Neoplasie Sangue Onlus
Layout table for additonal information
Responsible Party: Fondazione Neoplasie Sangue Onlus Identifier: NCT00961467    
Other Study ID Numbers: RV MM PI 210
First Posted: August 19, 2009    Key Record Dates
Last Update Posted: May 10, 2016
Last Verified: May 2016
Keywords provided by Fondazione Neoplasie Sangue Onlus:
Relapsed/ refractory Multiple Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action